News
The FDA approved pegcetacoplan (EMPAVELI; Apellis Pharmaceuticals) as the first treatment for patients aged 12 and older with the rare, severe kidney diseases C3 glomerulopathy (C3G) and primary ...
2d
MedPage Today on MSNCaution Advised With Upfront SGLT2 Inhibitor-MRA Combo for Heart FailureIncluded in the open-label crossover SOGALDI-PEF study were adults with symptomatic heart failure (New York Heart Association ...
For metoprolol doses ≥100 mg (i.e., medium to high doses) and systolic blood pressure >100 mm Hg, carvedilol was started at 12.5 mg b.i.d.; otherwise (i.e., for patients receiving low to medium ...
Post-chemotherapy administration of 5 mg olanzapine in combination with triplet antiemetic therapy before anthracycline plus cyclophosphamide-based chemotherapy significantly improved the complete ...
2025 MG 5 pricing and specifications Budget-priced sedan now limited to turbocharged Essence variant Safety updates result in three-star ANCAP score, up from zero stars Priced from $32,990 drive-away ...
MG Australia cuts back 2025 MG 5 range The MG 5 will be offered in just one pricier model grade for the 2025 model year after a safety upgrade earned it a higher ANCAP rating.
Time marches on, and after a 2023 update, the MG ZS EV is about to be no more, replaced in the brand’s line-up by a newer SUV, the 2025 MG S5 EV.
The prices of the MG Astor begin at Rs 11.30 lakh (ex-showroom), and it competes against models like Hyundai Creta, Kia Seltos, and others.
2026 Kia Sportage price and features: Facelifted 2026 Toyota RAV4, Honda CR-V, Mazda CX-5, MG HS, Mitsubishi Outlander and Nissan X-Trail rival gets fresh looks, additional hybrid car options and ...
Read More About Toyota RAV4 2026 Toyota RAV4 takes shape ahead of official reveal: Everything we know about the new 2026 Hyundai Tucson, Kia Sportage, Mazda CX-5, MG HS, Mitsubishi Outlander, Nissan X ...
The larger battery pack makes the Windsor EV Pro more apt for long intercity runs, while the feature additions are an added bonus ...
Topline results were announced from a phase 3 study comparing aficamten with metoprolol in adults with symptomatic obstructive hypertrophic cardiomyopathy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results